Article Sidebar
Published:
Jul 7, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Luteolin attenuates high glucose-induced cytotoxicity by suppressing TXNIP expression in neuronal cells
Abstract
Purpose: To determine the potential effect of luteolin in neuroprotection using an in vitro model of diabetic neuropathy (DN) in PC12 cells by high glucose (HG)-induced neurotoxicity.
Methods: PC12 cells were pretreated with HG media for 3, 6, 12, and 24 h, followed by treatment with increasing concentrations of luteolin (10, 25, and 50 ug/ml) for 24 hours. Following luteolin treatment, the cells were transfected with a plasmid expressing thioredoxin-interacting protein (TXNIP). To evaluate HG-induced cytotoxicity, the expression levels of the inflammatory markers interleukin (IL)-8, IL-6, and tumor necrosis factor-α (TNF-α) were evaluated by quantitative reverse transcription PCR (qRT-PCR) and ELISA. In addition, the apoptotic cells were assessed by flow cytometry. The expression levels of TXNIP protein and mRNA were determined by western blotting and qRT-PCR, respectively.
Results: Luteolin decreased the expression levels of TNF-α, IL-1β, and IL-6 in a dose-dependent manner at both the protein and mRNA level. Luteolin also decreased HG-induced apoptosis in PC12 cells (p < 0.05). The expression of B-cell lymphoma 2 (BCL-2) was suppressed, whereas those of cleaved PARP and cleaved caspase-3 were increased following HG treatment. Luteolin treatment had the opposite effect in a dose-dependent manner (p < 0.05). Luteolin reduced HG-induced inflammation and apoptosis in PC12 cells by inhibiting TXNIP expression (p < 0.05).
Conclusion: These data indicate that the neuroprotective effects of luteolin is probably exerted its antiapoptotic and anti-inflammatory activities via the TXNIP pathway.
